Climb Bio, Inc. (CLYM) stock
CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.78−0.16 (-1.61%)
Close on Nov 17, 2026Market cap $561.73MP/E –Yield –
Climb Bio total assets
Total assets on the balance sheet at the end of each period.
Climb Bio's total assets was $246.29M at Jun 30, 2026. For fiscal 2025 it was $167.74M, down 22.8% from the year before. The highest annual figure on record is $217.19M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $167.74M | -22.8% |
| FY2024 | Dec 31, 2024 | $217.19M | +96.6% |
| FY2023 | Dec 31, 2023 | $110.47M | -18.2% |
| FY2022 | Dec 31, 2022 | $134.99M | -22.1% |
| FY2021 | Dec 31, 2021 | $173.24M | +603.3% |
| FY2020 | Dec 31, 2020 | $24.63M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $246.29M | +28.0% |
| Q1 FY2026 | Mar 31, 2026 | $152.37M | -24.1% |
| Q4 FY2025 | Dec 31, 2025 | $167.74M | -22.8% |
| Q3 FY2025 | Sep 30, 2025 | $182.30M | -18.0% |
| Q2 FY2025 | Jun 30, 2025 | $192.39M | -14.9% |
| Q1 FY2025 | Mar 31, 2025 | $200.74M | +83.6% |
| Q4 FY2024 | Dec 31, 2024 | $217.19M | +96.6% |
| Q3 FY2024 | Sep 30, 2024 | $222.20M | +97.1% |
| Q2 FY2024 | Jun 30, 2024 | $226.02M | +94.4% |
| Q1 FY2024 | Mar 31, 2024 | $109.33M | -10.4% |
| Q4 FY2023 | Dec 31, 2023 | $110.47M | -18.2% |
| Q3 FY2023 | Sep 30, 2023 | $112.74M | -20.0% |
| Q2 FY2023 | Jun 30, 2023 | $116.27M | -22.5% |
| Q1 FY2023 | Mar 31, 2023 | $122.09M | -24.8% |
| Q4 FY2022 | Dec 31, 2022 | $134.99M | -22.1% |
| Q3 FY2022 | Sep 30, 2022 | $140.86M | -22.7% |
| Q2 FY2022 | Jun 30, 2022 | $150.11M | +39.5% |
| Q1 FY2022 | Mar 31, 2022 | $162.42M | +559.4% |
| Q4 FY2021 | Dec 31, 2021 | $173.24M | – |
| Q3 FY2021 | Sep 30, 2021 | $182.25M | – |
| Q2 FY2021 | Jun 30, 2021 | $107.63M | – |
| Q4 FY2020 | Dec 31, 2020 | $24.63M | – |
See a number that looks wrong?